News
Market and company headlines
JNJAll
Loading
03:00-16:00Yesterday2 Stories
What Do Johnson & Johnson (JNJ) Cancer Trial Wins Mean For Its Stock?
Johnson & Johnson (NYSE: JNJ) reported new oncology data, including a 75% tumor response rate for JNJ-6143 in advanced prostate cancer. The RYBREVANT FASPRO regimen produced a 77% response rate as an initial treatment option in advanced head and neck cancer patients. ERLEADA use around surgery reduced recurrence and death risk in high risk prostate cancer, while an orthopedics merger with Smith & Nephew collapsed over leadership disagreements. The fresh JNJ-6143 and RYBREVANT FASPRO trial...
Johnson & Johnson Prostate Cancer Drug Shrinks Tumors In Early Stage Trial
Key Stats for Johnson & Johnson StockPrice change for Johnson & Johnsonstock in the last 6 months: 16%$JNJ Stock Price as of Oct. 23: $26452-Week High: $281$JNJ Stock Price Target: $279__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__>>> What Happened?Johnson & Johnson (JNJ:NYSE) said its experimental prostate cancer pill caused tumors to shrink or disappear in an early-stage trial.
03:00-22:00Oct 252 Stories
Johnson & Johnson Won UK Approval for Its Psoriasis Pill. Here’s Where the Stock Could Go by 2030
Key Stats for Johnson & Johnson StockCurrent Price: $263. 81Target Price (Mid): ~$342Street Target: ~$279Potential Total Return: ~30%Annualized IRR: ~6% / year__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__ >>> What Happened?Johnson & Johnson (JNJ) closed at $263.
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
Johnson & Johnson (NYSE:JNJ) today announced promising Phase 1 results for JNJ-6143 (formerly HLD-0915), an investigational once-daily oral Regulated Induced Proximity Targeting Chimera (RIPTAC) small molecule, in patients with advanced prostate cancer who had received multiple prior treatments. Among patients with measurable disease, 75 percent (12 out of 16) had a confirmed complete or partial response assessed by Response Evaluation Criteria in Solid Tumors (RECIST). At the 50 mg dose, 77 per
05:00-13:00Oct 242 Stories
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?
Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given for six months before and after surgery, with radical prostatectomy alone in patients with high-risk localized or locally advanced prostate cancer. The apalutamide plus ADT regimen reduced the risk of disease recurrence or death by 62 percent compared with surgery alone. The regimen also showed a n
10:00-14:00Oct 233 Stories
Smith And Nephew Merger Talks With Johnson & Johnson Collapse Over Leadership Dispute
Key Stats for Johnson & Johnson StockPrice change for Johnson & Johnson stock in last 6 months: 14%$JNJ Stock Price as of Oct. 22: $26752-Week High: $281$JNJ Stock Price Target: $279__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__>>> What Happened?Smith & Nephew held merger talks with Johnson & Johnson (JNJ:NYSE) to combine with J&J’s orthopedics division.
Correction: Update: Market Chatter: Johnson & Johnson Orthopedics, Smith & Nephew Merger Collapsed Over Leadership Dispute
(Corrects to clarify that Smith & Nephew declined to comment and updates the second paragraph with m
04:00-07:00Oct 232 Stories
Johnson & Johnson's Icotrokinra Hydrochloride Receives Medicines And Healthcare Products Regulatory Agency Approval To Treat Moderate To Severe Plaque Psoriasis
https://www.gov.uk/government/news/mhra-approves-new-oral-treatment-for-moderate-to-severe-plaque-psoriasis
Update: Market Chatter: Johnson & Johnson Orthopedics, Smith & Nephew Merger Collapsed Over Leadership Dispute
(Updates with Smith & Nephew's response in the fifth paragraph.) Johnson & Johnson's (JNJ) orthop
11:00-13:00Oct 222 Stories
Procter & Gamble Jumps 6% as Earnings Beat Draws Defensive Buyers; Johnson & Johnson Rises 3%, Coca-Cola Ticks Up
Procter & Gamble is surging on a strong earnings beat, but a collapsing gross margin and soaring commodity costs are quietly building pressure beneath the headline numbers. Whether lower-income shoppers keep absorbing higher prices will decide if this rally holds.
Johnson & Johnson Deepens its Long-Term Commitment to Hong Kong Through OASES Strategic Enterprise Collaboration
Johnson & Johnson today announced that it has been selected as a Strategic Enterprise by the Hong Kong SAR Government's Office for Attracting Strategic Enterprises (OASES), marking a new chapter in the company's long-standing collaboration with Hong Kong. Johnson & Johnson sees strong alignment with Hong Kong's Five-Year Plan ambition to develop Hong Kong into a Health and Medical Innovation Hub with global influence. Building on more than five decades in the city, Johnson & Johnson will work al
08:00-10:00Oct 222 Stories
JNJ Stock Has a New Growth Story, but One Business Needs to Catch Up
Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals like Merck and AbbVie.
Is Johnson & Johnson Stock Ready For A MedTech Stall?
For questions about this article or underlying research, email help@trefis.com.
03:00-08:00Oct 222 Stories
Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
IRVINE, Calif., October 22, 2026--Johnson & Johnson reports first real-world VARIPULSE Pro Platform data and 12-Month OMNYPULSE Platform outcomes for atrial fibrillation treatment
Johnson & Johnson Announces Data From Its VARIPURE, Omny-IRE Trials Demonstrated 100% Of Participants Had Acute Procedural Success; Mean Ablation Rate Of 17.9 Minutes Observed
Johnson & Johnson (NYSE: JNJ) today announced new data from the late-breaking VARIPURE and Omny-IRE studies presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 Annual Meeting in Busan, South Korea. Both
13:00-15:00Oct 212 Stories
Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?
Johnson and Johnson has raised its dividend every single year for 64 years straight, yet a plain S&P 500 index fund still beat it handily over the past decade. Understanding why reveals something surprising about what actually kept long-term shareholders afloat.
Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?
Johnson & Johnson (NYSE:JNJ) raised its 2026 forecast earlier this month. It now expects full-year sales of about $101.2 billion at the midpoint, a little higher than its July outlook, and slightly higher adjusted earnings per share too. The company is one of the 10 No-Brainer Stocks to Buy Now. But the quarter behind that […]
08:00-11:00Oct 212 Stories
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026
The market has rewarded this biotech for its breakthroughs.
Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now?
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
04:00-08:00Oct 212 Stories
Johnson & Johnson’s Profit Fell 96% Year-Over-Year. But the Dividend Has Risen for 64 Years in a Row
Johnson and Johnson just posted a 96% profit collapse, yet on the same day raised its full-year guidance and extended a dividend streak most companies only dream about. The reason the headline number is almost completely misleading tells you everything about how to read this stock.
Global Life Science Market Report 2026: Size, Trends and Forecast to 2030 | Secure $200.6B AI and Precision Medicine Upside with Johnson & Johnson, Roche, Pfizer, and AstraZeneca
Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Life Science Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global life science market is experiencing rapid expansion, supported by rising pharmaceutical research and development investment, biotechnology innovation, laboratory automation, and growing demand for advanced diagnostics. The market is projected to increase from $109.53 billion in 2025 to $123.41 billion in 2026, representing a compound annual growth rate of 12
12:00Oct 202 Stories
Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?
Johnson & Johnson (NYSE:JNJ) is turning acquired heart technologies into growing sales. Adoption of treatments for hardened arteries supports that strategy, while competition and development spending raise the cost of maintaining its lead. A larger hospital network creates opportunities, but shareholders need ownership to deliver more than a bigger revenue base. Johnson & Johnson (NYSE:JNJ) […]
Johnson & Johnson (JNJ) Debuts New Coronary Catheter In The U.S.
Johnson & Johnson (NYSE:JNJ) introduced the Shockwave C2 Aero Fly Coronary IVL Catheter in the U.S. for calcified coronary lesions. The new catheter is described by the company as a next generation device intended to improve procedural efficiency in coronary interventions. Johnson & Johnson reported long term Phase 3 and extension trial data for TREMFYA and ICOTYDE in Crohn’s disease and plaque psoriasis. The fresh coronary IVL launch and TREMFYA and ICOTYDE data only capture part of the...
07:00-09:00Oct 203 Stories
Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat
Johnson & Johnson's Q3 earnings beat fails to prevent a 6% stock drop, but three healthcare ETFs offer diversified exposure to its growth potential.
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
SANTA CLARA, Calif., October 20, 2026--Next-generation IVL catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease.
09:00-11:00Oct 192 Stories
Johnson & Johnson’s Dividend Machine Is Running. Can Earnings Keep Up?
Johnson & Johnson (NYSE:JNJ) stands out in the healthcare world for a reason. Its massive scale, strong research teams, and deep relationships with hospitals and medical professionals give it an edge that’s tough for competitors to match. The company’s Innovative Medicine branch creates treatments for tough diseases, while its MedTech division provides equipment for surgeries, […]
Is Johnson & Johnson (JNJ) Undervalued Following Its Latest Oncology Update?
Johnson & Johnson (JNJ) stock is under fresh scrutiny after European regulators recommended expanding TALVEY’s use in relapsed or refractory multiple myeloma, adding another data backed oncology asset to the healthcare giant’s pipeline. For investors tracking the bigger picture, Johnson & Johnson’s recent drug updates, dividend affirmation and third quarter earnings all land against a share price of US$255.56, with a year to date share price return of 23.25% and a 1 year total shareholder...
08:00Oct 192 Stories
Has Johnson & Johnson Stock Become A Different Bet?
Investors are paying a premium for Johnson & Johnson (JNJ) stock. It trades at 29.2 times earnings, compared to 22.9 for the S&P 500. Shareholders paying that premium need to understand exactly what they are buying, and the priorities at the company have changed. A year ago, during the fiscal Q3 2025 call, executives emphasized how the business would maintain growth despite the loss of exclusivity for STELARA, which is the point when rivals can sell copies of a drug. The corporate focus has shif
Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
Johnson & Johnson (NYSE: JNJ) today announced one-year results from the Phase 3 FUZION study showing TREMFYA® (guselkumab) maintained or improved fistula remission through 48 weeks in adults with Crohn's disease (CD).1 The findings build on the previously reported Week 24 results and further support the use of TREMFYA in one of the most difficult-to-treat manifestations of CD 2. The late-breaking findings are being presented at the 2026 United European Gastroenterology Week (UEG Week).
04:00-08:00Oct 192 Stories
Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead
Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is what the numbers actually say about whether this healthcare giant earns its premium valuation.
Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease
TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose groupThese findings build on the Phase
06:00Oct 171 Story
14:00-22:00Oct 162 Stories
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol-Myers trades at a significant valuation discount, but its higher leverage and patent risks contrast sharply with Johnson & Johnson's diversified stability.
Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum.
06:00-09:00Oct 162 Stories
Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $287
Wells Fargo analyst Larry Biegelsen maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $275 to $287.
Does Raised 2026 Outlook Change The Bull Case For Johnson & Johnson (JNJ)?
Johnson & Johnson reported third quarter 2026 sales of US$25,399 million and net income of US$210 million, raised its full year outlook, and affirmed a US$1.34 per share fourth quarter dividend payable in December 2026. Strong demand for TREMFYA, early momentum for ICOTYDE, and continued focus on oncology helped offset weaker MedTech performance and international pricing pressure for Johnson & Johnson. We will look at how Johnson & Johnson's raised 2026 guidance, despite softer MedTech...
04:00Oct 161 Story
08:00-10:00Oct 152 Stories
Where Could Johnson & Johnson's Next Growth Come From?
Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors paying that premium appear to be counting on more growth. The company raised its 2026 guidance on October 13, and Chief Executive Joaquin Duato pointed to one new product as one of its most transformative MedTech innovations. So which product is it.
Morgan Stanley Maintains Overweight on Johnson & Johnson, Lowers Price Target to $292
Morgan Stanley analyst Terence Flynn maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and lowers the price target from $294 to $292.
06:00Oct 151 Story
14:00Oct 141 Story
09:00Oct 112 Stories
Dear Johnson & Johnson Stock Fans, Mark Your Calendars for October 13
Johnson & Johnson will report its third-quarter results on Oct. 13.
Johnson & Johnson Stock Has Surged 44%, Can Its Growth Justify the Valuation?
Johnson & Johnson (NYSE:JNJ) is no longer trading like a stock that investors have simply overlooked. The shares closed at $264.74 on September 30, considerably up from $185.42 a year earlier, or around 41.66%. Over the same period, the S&P 500 gained about 14.41%. There are nine healthcare stocks other than JNJ in our ranking […]
08:00Oct 101 Story
07:00-17:00Oct 92 Stories
Coca-Cola (NYSE:KO) & Johnson & Johson (NYSE:JNJ): Buy Them For The Dividends, Says Jim Cramer
Coca-Cola (NYSE:KO) and Johnson & Johnson (NYSE:JNJ), while operating in completely different industries, factored into the discussion in Cramer’s October 2nd morning appearance. The CNBC TV host discussed the two as stocks that could be bought on the back of weakness in the economy indicated through the jobs report, which saw the US add a […]
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric patients 12 years of age and older (adolescents) with moderate-to-severe plaque psoriasis.
03:00Oct 91 Story
17:00Oct 81 Story
15:00Oct 31 Story
06:00-10:00Oct 22 Stories
Johnson & Johnson (JNJ) IMAAVY Data Puts Its Undervalued Narrative Back In Focus
Johnson & Johnson (JNJ) is back in focus after new IMAAVY data in generalized myasthenia gravis, giving investors fresh insight into how its immunology pipeline might complement the stock’s recent double digit one year return. Despite the IMAAVY update and a string of recent drug data releases across immunology, oncology and neuroscience, Johnson & Johnson’s share price has eased in the short term, with the stock down 4.4% over the past week and 4.6% over the past month. However, a 24.8% year...
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
Johnson & Johnson (NYSE: JNJ) today announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE® (icotrokinra) on high-impact plaque psoriasis (PsO) sites. ICOTYDE is the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric patients 12 years of age and older (adolescents).
02:00Oct 21 Story
15:00-19:00Oct 12 Stories
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale
Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.
07:00-13:00Oct 12 Stories
JNJ or MRK: One Dividend Is Built to Last, One Faces a Reckoning
Both JNJ and MRK have surged in 2026, but a looming patent cliff and a balance sheet loaded with acquisition debt mean one of these pharma dividends faces a reckoning that retirement investors cannot afford to ignore.
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
JACKSONVILLE, Fla., October 01, 2026--New global survey by Johnson & Johnson finds most women don’t connect eye health changes with menopause